Verinata Licenses Quake Patent, Setting Stage for IP Tussle with Sequenom | GenomeWeb

By Monica Heger

Verinata Health has licensed a patent recently issued to Stephen Quake of Stanford University for the use of next-generation sequencing to diagnose fetal aneuploidies, the company said last week.

Verinata is currently developing a next-gen sequencing-based fetal trisomy diagnostic based on the technology. However, Sequenom believes that the development of such a test would infringe a patent it currently holds.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.